Ignite Creation Date:
2024-05-06 @ 3:48 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04767529
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-04-21
First Post:
2021-02-16
Brief Title:
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis NASH
Sponsor:
Akero Therapeutics Inc
Organization:
Akero Therapeutics Inc
Study Overview
Official Title:
A Phase 2b Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis NASH
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Harmony
Brief Summary:
This is a multi-center evaluation of efruxifermin EFX in a randomized double-blind placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None